RHYTHM PHARMACEUTICALS

rhythm-pharmaceuticals-logo

Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Their lead peptide product candidate, setmelanotide, is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of rare genetic disorders of obesity. They believe that setmelanotide, for which they have exclusive worldwide rights, has the potential to serve as replacement therapy for the treatment of melanocortin 4, or MC4, pathway deficiencies. The MC4 pathway is a compelling target for treating these genetic disorders because of its critical role in regulating appetite and weight, and peptide therapeutics are uniquely suited to activating this target.
#People #Financial #Event #Website #More

RHYTHM PHARMACEUTICALS

Social Links:

linkedin

Linkedin

twitter

Twitter

Industry:
Biotechnology Pharmaceutical Therapeutics

Founded:
2010-02-01

Address:
Boston, Massachusetts, United States

Country:
United States

Website Url:
http://www.rhythmtx.com

Total Employee:
101+

Status:
Active

Total Funding:
637.7 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics



Current Advisors List

elizabeth-stoner_image

Elizabeth Stoner Senior Clinical Advisor @ Rhythm Pharmaceuticals
Advisor
2010-01-01

steven-peter_image

Steven Peter Board Member @ Rhythm Pharmaceuticals
Board_member

ed-mathers_image

Ed Mathers Board Member @ Rhythm Pharmaceuticals
Board_member

Current Employees Featured

david-connolly_image

David Connolly
David Connolly Head of Investor Relations and Corporate Communications @ Rhythm Pharmaceuticals
Head of Investor Relations and Corporate Communications
2019-05-01

michelle-hylan_image

Michelle Hylan
Michelle Hylan Clinical Consultant @ Rhythm Pharmaceuticals
Clinical Consultant
2014-06-01

hunter-smith_image

Hunter Smith
Hunter Smith Chief Financial Officer @ Rhythm Pharmaceuticals
Chief Financial Officer

pamela-cramer_image

Pamela Cramer
Pamela Cramer Chief Human Resources Officer @ Rhythm Pharmaceuticals
Chief Human Resources Officer

joe-shulman_image

Joe Shulman
Joe Shulman Chief Technical Officer @ Rhythm Pharmaceuticals
Chief Technical Officer
2022-02-01

linda-shapiro-manning_image

Linda Shapiro Manning
Linda Shapiro Manning Chief Medical Officer (CMO) @ Rhythm Pharmaceuticals
Chief Medical Officer (CMO)
2021-09-10

irene-aquino_image

Irene Aquino
Irene Aquino Vice President, Patient Advocacy and Customer Engagement @ Rhythm Pharmaceuticals
Vice President, Patient Advocacy and Customer Engagement
2021-02-01

jennifer-chien_image

Jennifer Chien
Jennifer Chien Executive Vice President, Head of North America @ Rhythm Pharmaceuticals
Executive Vice President, Head of North America
2020-11-01

patrick-kleyn_image

Patrick Kleyn
Patrick Kleyn SVP and Head of Translational Research and Development @ Rhythm Pharmaceuticals
SVP and Head of Translational Research and Development
2022-02-01

lex-ht-van-der-ploeg_image

Lex H.T. Van der Ploeg
Lex H.T. Van der Ploeg Consultant @ Rhythm Pharmaceuticals
Consultant
2019-07-01

Founder


bart-henderson_image

Bart Henderson

elizabeth-stoner_image

Elizabeth Stoner

Stock Details


Company's stock symbol is NASDAQ:RYTM

Investors List

healthcare-royalty-partners_image

HealthCare Royalty Partners

HealthCare Royalty Partners investment in Post-IPO Debt - Rhythm Pharmaceuticals

ipsen_image

Ipsen

Ipsen investment in Venture Round - Rhythm Pharmaceuticals

third-rock-ventures_image

Third Rock Ventures

Third Rock Ventures investment in Venture Round - Rhythm Pharmaceuticals

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Venture Round - Rhythm Pharmaceuticals

orbimed-advisors_image

OrbiMed

OrbiMed investment in Venture Round - Rhythm Pharmaceuticals

deerfield-management_image

Deerfield Capital Management

Deerfield Capital Management investment in Venture Round - Rhythm Pharmaceuticals

mpm-capital_image

MPM Capital

MPM Capital investment in Venture Round - Rhythm Pharmaceuticals

pfizer-venture-investments_image

Pfizer Venture Investments

Pfizer Venture Investments investment in Venture Round - Rhythm Pharmaceuticals

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Series A - Rhythm Pharmaceuticals

mpm-capital_image

MPM Capital

MPM Capital investment in Series A - Rhythm Pharmaceuticals

Official Site Inspections

http://www.rhythmtx.com Semrush global rank: 1.77 M Semrush visits lastest month: 13.17 K

  • Host name: 141.193.213.21
  • IP address: 141.193.213.21
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Rhythm Pharmaceuticals" on Search Engine

Rhythm Pharmaceuticals - Crunchbase Company Profile & Funding

About. Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics. Boston, Massachusetts, United States. …See details»

About – Rhythm Pharmaceuticals

Product. Science. Scientific Overview. MC4R Pathway. Our Research. Our Focus. Publications. Clinical Trials. Overview. Emanate. Daybreak. Understanding Clinical …See details»

Rhythm Pharmaceuticals Inc. | LinkedIn

Rhythm Pharmaceuticals Inc. | 26,861 followers on LinkedIn. Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare MC4R pathway...See details»

Rhythm Pharmaceuticals, Inc. (RYTM) - Yahoo Finance

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.See details»

Investor Overview | Rhythm Pharmaceuticals, Inc.

Apr 24, 2024 Company Overview. Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company committed to transforming the care for patients living with …See details»

Rhythm Pharmaceuticals Announces First Patient Dosed in …

BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on …See details»

News | Rhythm Pharmaceuticals, Inc.

6 days ago Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan. February 22, 2024. Rhythm …See details»

Rhythm Pharmaceuticals Secures $150 Million in Convertible

Apr 1, 2024 Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing. -- Proceeds from financing and existing cash on-hand sufficient to fund …See details»

Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V.

BOSTON and AMSTERDAM, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical …See details»

Rhythm Pharmaceuticals Reports First Quarter 2023 Financial …

BOSTON, May 02, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on …See details»

Rhythm Pharmaceuticals, Inc. Announces Closing of $124.8 …

BOSTON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a commercial-stage biopharmaceutical company focused …See details»

Rhythm Pharmaceuticals - Funding, Financials, Valuation

Organization. Rhythm Pharmaceuticals. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Stock Symbol …See details»

Rhythm Pharmaceuticals Company Profile 2024: Stock …

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases.See details»

RHYTHM PHARMACEUTICALS, INC. FORM 10-K SECURITIES …

RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 46-2159271 (State or other jurisdiction of (I.R.S. Employer incorporation or …See details»

Rhythm Pharmaceuticals - Life Sciences Ontario Site

Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by …See details»

Rhythm Pharmaceuticals Reports Q1 2024 Results: Revenue …

May 7, 2024 The first quarter of 2024 marked a significant period for Rhythm Pharmaceuticals with a reported net loss of $141.4 million, or a loss of $2.35 per share, …See details»

5 Analysts Assess Rhythm Pharmaceuticals: What You Need To …

Apr 10, 2024 Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases.See details»

Rhythm Pharmaceuticals Announces New Employment …

4 days ago Published: May 09, 2024. BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage …See details»

Press Release Distribution and Management - GlobeNewswire

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on …See details»

Rhythm Pharmaceuticals Q1 2024 Earnings Preview - Seeking …

May 6, 2024 Rhythm Pharmaceuticals ( NASDAQ: RYTM) is scheduled to announce Q1 earnings results on Tuesday, May 7th, before market open. The consensus EPS …See details»

dfkcompany.com © 2022. All rights reserved